Why the study?
Does bivalirudin compared to heparin improve outcomes or safety in patients with ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention?
Does bivalirudin compared to heparin improve outcomes or safety in patients with ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
In STEMI patients undergoing PCI, anticoagulation choice should be individualized, favoring bivalirudin for high bleeding risk and heparin for high stent thrombosis risk.
Bivalirudin and heparin are the major available parenteral anticoagulants for percutaneous coronary intervention (PCI) in ST-segment-elevation myocardial infarction. Even though hard clinical outcomes are comparable with both drugs, bivalirudin appears to be safer (less bleeding events) at the expense of lower short-term efficacy (more acute stent thrombosis events). The selection of anticoagulation during PCI in ST-segment-elevation myocardial infarction should be individualized, taking into account the patient's ischemic and bleeding risk. In patients with increased bleeding risk, bivalirudin might be preferable to heparin, whereas in complex PCI with increased risk for stent thrombosis, heparin is preferable. Further clinical studies are needed to elucidate the role of these drugs in PCI for ST-segment-elevation myocardial infarction in the era of radial approaches, new potent antiplatelet agents and the use of glycoprotein IIb/IIIa inhibitors.
No takes yet. Share an insight, caveat, or question.
Mavrakanas et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: